CO6741219A2 - Inhibidores de catepsina c - Google Patents

Inhibidores de catepsina c

Info

Publication number
CO6741219A2
CO6741219A2 CO13190045A CO13190045A CO6741219A2 CO 6741219 A2 CO6741219 A2 CO 6741219A2 CO 13190045 A CO13190045 A CO 13190045A CO 13190045 A CO13190045 A CO 13190045A CO 6741219 A2 CO6741219 A2 CO 6741219A2
Authority
CO
Colombia
Prior art keywords
cathepsin
inhibitors
butenamides
amino
formula
Prior art date
Application number
CO13190045A
Other languages
English (en)
Inventor
Christopher E Neipp
Michael R Palovich
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46638952&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6741219(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of CO6741219A2 publication Critical patent/CO6741219A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se describen 4-amino-2-butenamidas de la Fórmula (I) que tienen actividad farmacológica, composiciones farmacéuticas que las contienen, y métodos para el tratamiento de enfermedades mediadas por la enzima catepsina C tales como la enfermedad pulmonar obstructiva crónica.
CO13190045A 2011-02-11 2013-08-09 Inhibidores de catepsina c CO6741219A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161441840P 2011-02-11 2011-02-11

Publications (1)

Publication Number Publication Date
CO6741219A2 true CO6741219A2 (es) 2013-08-30

Family

ID=46638952

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13190045A CO6741219A2 (es) 2011-02-11 2013-08-09 Inhibidores de catepsina c

Country Status (23)

Country Link
US (2) US8841463B2 (es)
EP (1) EP2672821B9 (es)
JP (1) JP5931929B2 (es)
KR (1) KR20140048857A (es)
CN (1) CN103491777B (es)
AR (1) AR085163A1 (es)
AU (1) AU2012214405B2 (es)
BR (1) BR112013020510A2 (es)
CA (1) CA2827157A1 (es)
CL (1) CL2013002325A1 (es)
CO (1) CO6741219A2 (es)
DO (1) DOP2013000182A (es)
EA (1) EA023168B1 (es)
ES (1) ES2583091T3 (es)
IL (1) IL227814A0 (es)
MA (1) MA34961B1 (es)
MX (1) MX2013009279A (es)
PE (1) PE20140999A1 (es)
SG (1) SG192669A1 (es)
TW (1) TW201302736A (es)
UY (1) UY33905A (es)
WO (1) WO2012109415A1 (es)
ZA (1) ZA201306074B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014091443A1 (en) 2012-12-13 2014-06-19 Glaxo Group Limited Cathepsin c inhibitors for treating cystic fibrosis, non-cystic fibrosis bronchiectasis, and anca-associated vasculitis
NO2699580T3 (es) 2014-01-24 2018-02-24

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2622581B1 (fr) * 1987-11-03 1990-02-16 Inorgan Sa Rech Develop Pharm Nouveaux derives de l-proline, leur preparation et leurs applications biologiques
CN1240355A (zh) * 1996-05-01 2000-01-05 伊莱利利公司 蛋白激酶c抑制剂增强溶癌剂和放射治疗的临床功效的用途
US6232299B1 (en) 1996-05-01 2001-05-15 Eli Lilly And Company Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy
US6214799B1 (en) 1996-05-14 2001-04-10 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds and methods for their use and preparation
WO2002048097A1 (en) * 2000-12-12 2002-06-20 Corvas International, Inc. Compounds, compositions and methods for treatment of parasitic infections
CN104370914B (zh) 2007-04-12 2018-09-07 辉瑞大药厂 作为蛋白酶c抑制剂的3-酰氨基-吡咯并[3,4-c]吡唑-5(1h,4h,6h)甲醛衍生物
KR20120034639A (ko) * 2009-05-07 2012-04-12 아스트라제네카 아베 치환된 1-시아노에틸헤테로시클릴카르복스아미드 화합물 750
UY32827A (es) 2009-08-12 2011-02-28 Glaxo Group Ltd Inhibidores de catepsina c
WO2012119941A1 (en) 2011-03-04 2012-09-13 Prozymex A/S Peptidyl nitrilcompounds as peptidase inhibitors

Also Published As

Publication number Publication date
EP2672821B9 (en) 2016-11-23
IL227814A0 (en) 2013-09-30
WO2012109415A1 (en) 2012-08-16
EA023168B1 (ru) 2016-04-29
US20140364476A1 (en) 2014-12-11
CL2013002325A1 (es) 2014-01-03
JP5931929B2 (ja) 2016-06-08
MA34961B1 (fr) 2014-03-01
US20130324584A1 (en) 2013-12-05
UY33905A (es) 2012-08-31
JP2014506577A (ja) 2014-03-17
AR085163A1 (es) 2013-09-11
KR20140048857A (ko) 2014-04-24
EP2672821B1 (en) 2016-04-20
EP2672821A4 (en) 2014-08-06
DOP2013000182A (es) 2014-03-16
SG192669A1 (en) 2013-09-30
CN103491777B (zh) 2015-05-06
ZA201306074B (en) 2014-04-30
MX2013009279A (es) 2013-10-28
CA2827157A1 (en) 2012-08-16
US8841463B2 (en) 2014-09-23
BR112013020510A2 (pt) 2016-07-12
CN103491777A (zh) 2014-01-01
AU2012214405A1 (en) 2013-04-18
PE20140999A1 (es) 2014-09-11
TW201302736A (zh) 2013-01-16
US9187461B2 (en) 2015-11-17
EA201391155A1 (ru) 2014-01-30
ES2583091T3 (es) 2016-09-19
AU2012214405B2 (en) 2015-07-23
EP2672821A1 (en) 2013-12-18
NZ614540A (en) 2015-03-27

Similar Documents

Publication Publication Date Title
AU2018236800B2 (en) DNA-PK inhibitors
DOP2012000257A (es) Derivados del acido 1-amino-2-ciclopropiletilboronico
PE20180318A1 (es) Procedimiento para preparar isoquinolinonas y formas solidas de isoquinolinonas
CO6551666A2 (es) Macrociclos como inhibidores del factor de coagulacion (fxia)
ECSP14013159A (es) Compuestos inhibidores de metaloenzimas
EA201391719A1 (ru) Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
CL2013001340A1 (es) Compuestos derivados de isoindol-amida, pirrolo-piridin-amida y pirrolo-pirimimidin-amida, inhibidores de nampt y rock; composicion farmaceutica; y metodo para tratar hiperetension, insuficiencia cardiaca cronica, aterosclerosis, asma, enfermedad de alzheimer, enfermedad de parkinson y glaucoma, entre otras enfermedades.
CU20140072A7 (es) Derivados de dihidro-oxazina y dihidro-pirido-oxazina
GT201400016A (es) Indazoles
EA201590975A1 (ru) Ингибиторы prmt5 и их применение
CR20130588A (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace 2
BR112014002202A2 (pt) macrociclos como inibidores de fator xia
EA201491028A1 (ru) Способ получения замещенных 5-фтор-1н-пиразолопиридинов
EA201892339A3 (ru) Несиалированный выделенный полипептид, способ получения указанного полипептида и фармацевтическая композиция для лечения воспалительного заболевания
CL2016001543A1 (es) Derivados del isocromeno como inhibidores de las fosfoinositido-3 quinasas.
BR112014004560A2 (pt) compostos e composições como inibidores de c-kit quinase
BR112013001753A2 (pt) método para preparar uma composição d einter-alfa-inibidor (iaip) eriquecida de plasma, solução aquosa de iaip, e, método para tratar uma doença ou distúrbio associado com disfunção de iaip e associado com atividadede protease de serina no plasma aumentada.
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
WO2013052943A3 (en) Small molecule inhibitors of mcl-1 and uses thereof
BR112014004319A2 (pt) compostos e composições como inibidores de c-kit cinase
EA201400976A1 (ru) Бензодиоксаны в комбинации с другими активными средствами для ингибирования продуцирования лейкотриена
CA2878796C (en) Derivatives of pyridinone as inhibitors for tissue transglutaminase
BR112014012459A2 (pt) 2h-indazóis como antagonistas do receptor de ep2
EA201201296A1 (ru) Способы лечения диабетических язв стопы